AstraZeneca PLC said Wednesday that analysis of its Covid-19 vaccine Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia syndrome after a second dose.
The estimated rate of thrombosis with thrombocytopenia syndrome was 2.3 for every million vaccines, with incidence rates comparable to those among unvaccinated individuals, the Cambridge, U.K.-based pharmaceutical company said.
After the first dose, the rate was 8.1 per million vaccines, AstraZeneca said.
No specific risk factors or definitive cause have been identified in the safety data, the company said.
AstraZeneca said the data was published in the medical journal The Lancet, and that its database included reported cases of thrombosis with thrombocytopenia syndrome globally up to April 30 occurring within 14 days of administration of the first or second dose of its vaccine.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.